دورية أكاديمية
Investigation of Mirabegron-loaded Nanostructured Lipid Carriers for Improved Bioabsorption: Formulation, Statistical Optimization, and In-Vivo Evaluation.
| العنوان: | Investigation of Mirabegron-loaded Nanostructured Lipid Carriers for Improved Bioabsorption: Formulation, Statistical Optimization, and In-Vivo Evaluation. |
|---|---|
| المؤلفون: | Shah P; Department of Pharmaceutics, Maliba Pharmacy College, Uka Tarsadia University, Maliba Campus, Gopal Vidyanagar, Bardoli-Mahuva Road, Tarsadi, 394350, Surat, Gujarat, India. pranav.shah@utu.ac.in., Patel M; Department of Pharmaceutics, Maliba Pharmacy College, Uka Tarsadia University, Maliba Campus, Gopal Vidyanagar, Bardoli-Mahuva Road, Tarsadi, 394350, Surat, Gujarat, India., Kansara Y; Department of Pharmaceutics, Maliba Pharmacy College, Uka Tarsadia University, Maliba Campus, Gopal Vidyanagar, Bardoli-Mahuva Road, Tarsadi, 394350, Surat, Gujarat, India., Vyas B; Department of Pharmacology, Maliba Pharmacy College, Uka Tarsadia University, Surat, Gujarat, India., Prajapati P; Department Pharmaceutical Analysis & Quality Assurance, Maliba Pharmacy College, Uka Tarsadia University, Surat, Gujarat, India., Pradhan M; Department of Pharmaceutics, Gracious College of Pharmacy, Abhanpur, Chhattisgarh, India., Jain S; Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India. |
| المصدر: | AAPS PharmSciTech [AAPS PharmSciTech] 2024 Sep 25; Vol. 25 (7), pp. 222. Date of Electronic Publication: 2024 Sep 25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932 (Electronic) Linking ISSN: 15309932 NLM ISO Abbreviation: AAPS PharmSciTech Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York : Springer Original Publication: Arlington, VA : American Association of Pharmaceutical Scientists, c2000- |
| مواضيع طبية MeSH: | Thiazoles*/pharmacokinetics , Thiazoles*/chemistry , Thiazoles*/administration & dosage , Drug Carriers*/chemistry , Acetanilides*/pharmacokinetics , Acetanilides*/administration & dosage , Acetanilides*/chemistry , Nanostructures*/chemistry , Drug Liberation* , Biological Availability* , Lipids*/chemistry , Particle Size*, Animals ; Rats ; Administration, Oral ; Chemistry, Pharmaceutical/methods ; Molecular Docking Simulation/methods ; Male ; Rats, Wistar ; Urinary Bladder, Overactive/drug therapy |
| مستخلص: | Overactive bladder (OAB) is a usual medical syndrome that affects the bladder, and Mirabegron (MBG) is preferred medicine for its control. Currently, available marketed formulations (MYRBETRIQ® granules and MYRBETRIQ® ER tablets) suffer from low bioavailability (29-35%) hampering their therapeutic effectiveness and compromising patient compliance. By creating MBG nanostructured lipid carriers (MBG-NLCs) for improved systemic availability and drug release, specifically in oral administration of OAB treatment, this study aimed to address these issues. MBG-NLCs were fabricated using a hot-melt ultrasonication technique. MBG-GMS; MBG-oleic acid interaction was assessed by in silico molecular docking. QbD relied on the concentration of Span 80 (X1) and homogenizer speed (X2) as critical material attribute (CMA) and critical process parameter (CPP) respectively, while critical quality attributes (CQA) such as particle size (Y1) and cumulative drug release at 24 h (Y2) were estimated as dependent variables. 32 factorial design was utilized to investigate the interconnection in variables that are dependent and independents. Optimized MBG-NLCs with a particle size of 194.4 ± 2.25 nm were suitable for lymphatic uptake. A PDI score of 0.275 ± 0.02 and zeta potential of -36.2 ± 0.721 mV indicated a uniform monodisperse system with stable dispersion properties. MBG-NLCs exhibited entrapment efficiency of 77.3 ± 1.17% and a sustained release in SIF of 94.75 ± 1.60% for 24 h. MBG-NLCs exhibited the Higuchi model with diffusion as a release mechanism. A pharmacokinetic study in Wistar rats exhibited a 1.67-fold higher bioavailability as compared to MBG suspension. Hence, MBG-NLCs hold promise for treating OAB by improving MBG's oral bio absorption. (© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.) |
| References: | Digesu G, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22:105–8. https://doi.org/10.1002/nau.10099 . (PMID: 10.1002/nau.1009912579626) Stewart W, Rooyen V, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36. https://doi.org/10.1007/s00345-002-0301-4 . (PMID: 10.1007/s00345-002-0301-412811491) Reynolds W, Fowke J, Dmochowski R. The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep. 2016;11:8–13. https://doi.org/10.1007/s11884-016-0344-9 . (PMID: 10.1007/s11884-016-0344-9270572654821440) Belavic J. Mirabegron for overactive bladder. Nurse Pract. 2012;37:9–10. https://doi.org/10.1097/01.NPR.0000422213.00175.5d . (PMID: 10.1097/01.NPR.0000422213.00175.5d23165131) Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7:204–16. https://doi.org/10.1177/2042098616659412 . (PMID: 10.1177/2042098616659412276956225014049) Iitsuka H, Van Gelderen M, Katashima M, et al. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects. 2015;37:1031–44. https://doi.org/10.1007/s40261-013-0146-1 . An JH, Lim C, Kiyonga AN, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018;10:149. https://doi.org/10.3390/pharmaceutics10030149 . (PMID: 10.3390/pharmaceutics10030149301896456161252) Surawase R, Baheti K. Box Behnken design for optimization of mirabegron solid dispersion by fluidised bed processing. Res J Pharm Technol. 2022;15:1472–6. https://doi.org/10.52711/0974-360X.2022.00244 . (PMID: 10.52711/0974-360X.2022.00244) Raut P, Gambhire M. Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an oral drug delivery for overactive bladder. Pharm Nanotechnol. 2021;9:120–9. https://doi.org/10.2174/2211738509666210127143107 . (PMID: 10.2174/221173850966621012714310733504321) Mahor A, Singh P, Gupta R, et al. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. J Nanotechnol. 2023;2023:1–35. https://doi.org/10.1155/2023/4687959 . (PMID: 10.1155/2023/4687959) Puglia C. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304. https://doi.org/10.1016/j.ijpharm.2008.01.045 . (PMID: 10.1016/j.ijpharm.2008.01.04518343059) Khan AA, Mudassir J, Mohtar N. Advanced drug delivery to the lymphatic system: lipid-based nano-formulations. Int J Nanomed. 2013;8:2733–44. https://doi.org/10.2147/IJN.S41521 . (PMID: 10.2147/IJN.S41521) Viegas C, Patrício AB, Prata JM, et al. Solid lipid nanoparticles vs. nanostructured lipid carriers: A comparative review. Pharmaceutics. 2023;15:1593. https://doi.org/10.3390/pharmaceutics15061593 . (PMID: 10.3390/pharmaceutics150615933737604210305282) Shah P, Sarolia J, Vyas B, Wagh P, Kaur A, Mishra A. PLGA nanoparticles for nose to brain delivery of clonazepam formulation, optimization by 3 2 factorial design in vitro and in vivo evaluation. Curr Drug Deliv. 2020;18:805–24. https://doi.org/10.2174/1567201817666200708115627 . (PMID: 10.2174/1567201817666200708115627) Dhoranwala K, Shah P, Shah S. Formulation optimization of rosuvastatin calcium-loaded solid lipid nanoparticles by 3 2 full-factorial design. NanoWorld J. 2015;1:110–9. https://doi.org/10.17756/nwj.2015-015 . (PMID: 10.17756/nwj.2015-015) Meng X, Zhang H, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7:146–57. https://doi.org/10.2174/157340911795677602 . (PMID: 10.2174/157340911795677602215349213151162) Luan J, Zhang D, Hao L, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;114:255–60. https://doi.org/10.1016/j.colsurfb.2013.10.018 . (PMID: 10.1016/j.colsurfb.2013.10.01824211416) Kim M, Kim K, Sohn S, et al. Formulation and evaluation of nanostructured lipid carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) by box-behnken design. Int J Nanomedicine. 2019;14:8509–20. https://doi.org/10.2147/IJN.S215835 . (PMID: 10.2147/IJN.S215835317496186818673) Sharma V, Sharma P, Kumar V. In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Adv Chem. 2016;7:1–9. https://doi.org/10.1155/2016/5409387 . (PMID: 10.1155/2016/5409387) Baek J, Pham C, Myung C, et al. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. Int J Pharm. 2015;495:701–9. https://doi.org/10.1016/j.ijpharm.2015.09.054 . (PMID: 10.1016/j.ijpharm.2015.09.05426423175) Borderwala K, Rathod S, Shah P. Eudragit S 100 surface engineered nanostructured lipid carriers for colon targeting of 5 fluorouracil: optimization and in vitro and in vivo characterization. AAPS PharmSciTech. 2021;22:216–22. https://doi.org/10.1208/s12249-021-02099-3 . (PMID: 10.1208/s12249-021-02099-334386888) Jia LJ, Zhang DR, Li ZY, et al. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv. 2010;17:11–8. https://doi.org/10.3109/10717540903431586 . (PMID: 10.3109/1071754090343158619941406) Dasineh S, Akbarian M, Ebrahimi H, et al. Tacrolimus-loaded chitosan-coated nanostructured lipid carriers: preparation, optimization and physicochemical characterization. Appl Nanosci. 2021;11:1169–81. https://doi.org/10.1007/s13204-021-01744-4 . (PMID: 10.1007/s13204-021-01744-4) Chokshi N, Rawal S, Solanki D, et al. Fabrication and characterization of surface engineered rifampicin loaded lipid nanoparticulate systems for the potential treatment of tuberculosis: an in vitro and in vivo evaluation. J Pharm Sci. 2021;110:2221–32. https://doi.org/10.1016/j.xphs.2021.02.018 . (PMID: 10.1016/j.xphs.2021.02.01833610570) MacGregor JF, Bruwer M-J. A framework for the development of design and control spaces. J Pharm Innov. 2008;3:15–22. https://doi.org/10.1007/s12247-008-9023-5 . (PMID: 10.1007/s12247-008-9023-5) Bastogne T. Quality-by-design of nano-pharmaceuticals - a state of the art. Nanomedicine. 2017;13:1–9. https://doi.org/10.1016/j.nano.2017.05.014 . (PMID: 10.1016/j.nano.2017.05.014) Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11:97. https://doi.org/10.3390/pharmaceutics11020097 . (PMID: 10.3390/pharmaceutics11020097308235456410192) Zhao L, Tang B, Tang P, et al. Chitosan/Sulfobutylether-b-cyclodextrin nanoparticles for ibrutinib delivery: a potential nano formulation of novel kinase inhibitor. J Pharm Sci. 2019;109:1136–44. https://doi.org/10.1016/j.xphs.2019.10.007 . (PMID: 10.1016/j.xphs.2019.10.00731606544) Zhao X-L, et al. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil. Drug Dev Ind Pharm. 2010;36:773–80. https://doi.org/10.3109/03639040903485716 . (PMID: 10.3109/0363904090348571620136496) Van Teijlingen R, Meijer J, Takusagawa S, et al. Development and validation of LC–MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B. 2012;887:102–11. https://doi.org/10.1016/j.jchromb.2012.01.018 . (PMID: 10.1016/j.jchromb.2012.01.018) Fathi H, Allam A, Elsabahy M, et al. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B. 2018;162:236–45. https://doi.org/10.1016/j.colsurfb.2017.11.064 . (PMID: 10.1016/j.colsurfb.2017.11.064) Majima T, Matsukawa Y, Funahashi Y, et al. The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction. World J Urol. 2020;38:1–12. https://doi.org/10.1007/s00345-019-02939-9 . (PMID: 10.1007/s00345-019-02939-9) Chen L, Zheng Y. Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. Revista Da Associacoa Medico Brasileira. 2019;65:141–8. https://doi.org/10.1590/1806-9282.65.2.141 . (PMID: 10.1590/1806-9282.65.2.141) Awadeen R, Boughdady M, Meshali M. Quality by design approach for preparation of zolmitriptan/chitosan nanostructured lipid carrier particles-formulation and pharmacodynamic assessment. Int J Nanomedicine. 2020;15:8553–68. https://doi.org/10.2147/IJN.S274352 . (PMID: 10.2147/IJN.S274352331732927646415) Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2015;20:320–9. https://doi.org/10.3109/10837450.2013.867445 . (PMID: 10.3109/10837450.2013.86744524328553) Thakkar H, Desai J, Parmar M. Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil. Asian J Pharm. 2014;8:81–9. https://doi.org/10.4103/0973-8398.134921 . (PMID: 10.4103/0973-8398.134921) Mühlen Z, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149–55. https://doi.org/10.1016/s0939-6411(97)00150-1 . (PMID: 10.1016/s0939-6411(97)00150-19704911) Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;1:598–613. https://doi.org/10.1016/j.biopha.2018.04.055 . (PMID: 10.1016/j.biopha.2018.04.055) Ladan K, Glavač K. Statistical FT-IR spectroscopy for the characterization of 17 vegetable oils. Molecules. 2022;27:3190. https://doi.org/10.3390/molecules27103190 . (PMID: 10.3390/molecules27103190) Zheng M, Falkeborg M, Zheng Y, et al. Formulation and characterization of nanostructured lipid carriers containing a mixed lipids core. Colloids Surf A. 2013;430:76–84. https://doi.org/10.1016/j.colsurfa.2013.03.070 . (PMID: 10.1016/j.colsurfa.2013.03.070) Saupe A, Gordon K, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314:56–62. https://doi.org/10.1016/j.ijpharm.2006.01.022 . (PMID: 10.1016/j.ijpharm.2006.01.02216574354) Shah N, Seth A, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res. 2016;7:423–34. https://doi.org/10.1016/j.jare.2016.03.002 . (PMID: 10.1016/j.jare.2016.03.002272227474856836) Patil G, Patil N, Deshmukh P, et al. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artif Cells Nanomed Biotechnol. 2016;44:12–9. https://doi.org/10.3109/21691401.2014.909820 . (PMID: 10.3109/21691401.2014.90982024866725) Shah P, Chavda K, Vyas B, et al. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Deliv Transl Res. 2020;11:1166–85. https://doi.org/10.1007/s13346-020-00839-9 . (PMID: 10.1007/s13346-020-00839-9) Sattar A, Chen D, Jiang L, et al. Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Sci Rep. 2017;7:2289–310. https://doi.org/10.1038/s41598-017-02523-4 . (PMID: 10.1038/s41598-017-02523-4285364465442105) |
| فهرسة مساهمة: | Keywords: 32 Full factorial design; lymphatic targeting; mirabegron; molecular docking; nanostructured lipid carrier |
| المشرفين على المادة: | MVR3JL3B2V (mirabegron) 0 (Thiazoles) 0 (Drug Carriers) 0 (Acetanilides) 0 (Lipids) |
| تواريخ الأحداث: | Date Created: 20240925 Date Completed: 20240925 Latest Revision: 20240925 |
| رمز التحديث: | 20240926 |
| DOI: | 10.1208/s12249-024-02944-1 |
| PMID: | 39322792 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1530-9932 |
|---|---|
| DOI: | 10.1208/s12249-024-02944-1 |